{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Albain KS"],"funding":["NCI NIH HHS","National Cancer Institute, Department of Health and Human Services","Southwest Oncology Group"],"pagination":["2055-2063"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3140679"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["374(9707)"],"pubmed_abstract":["<h4>Background</h4>Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy.<h4>Methods</h4>We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concu"],"journal":["Lancet (London, England)"],"pubmed_title":["Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial."],"pmcid":["PMC3140679"],"funding_grant_id":["CA63844","U10 CA035176","U10 CA035178","CA58415","U10 CA032102","CA58416","CA58658","CA38926","CA45461","CA35090","U10 CA076447","CA04919","CA45466","U10 CA045377","N01 CA045807","N01 CA035431","CA58882","CA13612","CA12644","CA14028","CA03096","U10 CA058686","N01 CA046441","CA45450","CA25224","(SWOG)-8814, INT-0100","CA35261","U10 CA046113","CA76132","N01 CA063844","U10 CA035431","CA35431","CA67663","U10 CA046282","U10 CA022433","CA28862","U10 CA067663","CA42777","U10 CA046441","CA76462","U10 CA037981","CA37981","CA35200","U10 CA042777","U10 CA016385","CA32734","U10 CA035281","U10 CA077202","CA46282","U10 CA045807","CA46441","CA16385","CA35283","CA35281","CA60138","CA12213","CA77202-06","CA32102","N01 CA035119","CA35176","CA35178","U10 CA063844","N01 CA027057","N01 CA045560","U10 CA020319","CA52757","CA46113","CA76447","U10 CA058416","U10 CA045450","U10 CA014028","CA58686","CA45807","U10 CA013612","U10 CA012644","CA58723","U10 CA032102-31","U10 CA021115","U10 CA004919","U10 CA035261","U10 CA058882","CA22433","CA52623","CA45377","U10 CA027057","U10 CA045461","CA35996","CA35117","N01 CA032102","CA27057","U10 CA035192","CA35119","U10 CA025224","CA76429","CA45560","CA52654","CA46136","U10 CA052654","CA52650","U10 CA035119","CA52772","U10 CA046368","N01 CA004919","CA21115","CA02599","N01 CA035178","CA35192","N01 CA035176","N01 CA013612","CA58861","CA35128","U10 CA035128","CA58348","U10 CA058348","U10 CA058861","U10 CA035090","CA46368","CA35084","CA04920","CA20319","U10 CA045560"],"pubmed_authors":["Ravdin PM","Green SJ","Lichter AS","Muss HB","Osborne CK","Breast Cancer Intergroup of North America","Henderson IC","Burton GV","Pritchard KI","Levine EG","Ingle JN","Barlow WE","Abeloff MD","Albain KS","Schneider DJ","Lew D","Martino S","Farrar WB","Livingston RB","Cobau CD","Ketchel SJ"],"additional_accession":[]},"is_claimable":false,"name":"Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.","description":"<h4>Background</h4>Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy.<h4>Methods</h4>We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concu","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009 Dec","modification":"2025-04-04T19:31:18.512Z","creation":"2019-03-27T03:07:16Z"},"accession":"S-EPMC3140679","cross_references":{"pubmed":["20004966"],"doi":["10.1016/s0140-6736(09)61523-3","10.1016/S0140-6736(09)61523-3"]}}